EU FP7 research funding for an orphan drug (Orfadin®) and vaccine (Hep C) development: a success and a failure?

BACKGROUND: We considered the extent of the contribution of publicly funded research to the late-stage clinical development of pharmaceuticals and medicinal products, based on the European Commission (EC) FP7 research funding programme. Using two EC FP7-HEALTH case study examples—representing two ty...

Descripción completa

Detalles Bibliográficos
Autores principales: Schmidt, L., Sehic, O., Wild, C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8080091/
https://www.ncbi.nlm.nih.gov/pubmed/33910624
http://dx.doi.org/10.1186/s40545-021-00317-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8080091/
https://www.ncbi.nlm.nih.gov/pubmed/33910624
http://dx.doi.org/10.1186/s40545-021-00317-8

Ejemplares similares